Follistatin-344 vs KPV
Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Follistatin-344 and KPV (also searched as KPV vs Follistatin-344) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Follistatin-344 centers on muscle, while KPV leans toward inflammation. On indexed research, KPV is ahead (Follistatin-344: 5 studies, Human evidence; KPV: 6, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Follistatin-344 is strongest for muscle; KPV for inflammation.
- •Evidence: Follistatin-344 Human evidence (5 studies) vs KPV Human evidence (6).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Myostatin inhibition | Muscle growth
Anti-Inflammatory Tripeptide | Alpha-MSH Fragment
Follistatin-344 vs KPV: side-by-side
| Metric | Follistatin-344 | KPV |
|---|---|---|
| Class | Muscle | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human evidence |
| Studies indexed | 5 | 6 |
| Research level | Limited Research | Emerging |
| Strongest effect | Muscle & body comp | Inflammation & immune |
| Healing & recovery | 1.0 | 4.0▲ |
| Muscle & body comp | 5.0▲ | 0.0 |
| Metabolic & appetite | 2.0▲ | 0.0 |
| Neuro & mood | 1.0▲ | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 1.0 | 5.0▲ |
| Skin & aesthetics | 2.0▲ | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Follistatin-344 | KPV |
|---|---|---|
| Mechanism | Myostatin inhibitor | Interactions with immune cells, enhancing anti-inflammatory responses |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Follistatin-344?
### Follistatin-344 Summary Follistatin-344 is a glycoprotein that plays a crucial role in the regulation of muscle growth and development by inhibiting myostatin, a negative regulator of muscle mass. Its potential therapeutic applications are being explored in various fields, including muscle wasting disorders and regenerative medicine.
Full Follistatin-344 profile, mechanism & studies →What is KPV?
### KPV Summary KPV is a tripeptide composed of lysine, proline, and valine, which has garnered interest in research for its potential roles in modulating immune responses and promoting wound healing. Its implications in various therapeutic contexts, particularly in inflammatory conditions, are currently being explored.
Full KPV profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | KPV | 4.0/5 effect signal |
| Muscle | Follistatin-344 | 5.0/5 effect signal |
| Metabolic | Follistatin-344 | 2.0/5 effect signal |
| Neuro | Follistatin-344 | 1.0/5 effect signal |
| Inflammation | KPV | 5.0/5 effect signal |
| Skin | Follistatin-344 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Follistatin-344 and KPV?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Follistatin-344 vs KPV: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Follistatin-344 has 5 approved studies indexed (Human evidence), and KPV has 6 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Follistatin-344 or KPV better?
It depends on your goal. Follistatin-344 is strongest for muscle; KPV for inflammation. KPV has more indexed studies (6). See the goal-by-goal breakdown above.
Is Follistatin-344 or KPV better for weight loss?
Follistatin-344 shows the stronger metabolic & appetite profile (2.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Follistatin-344 or KPV better for muscle?
Follistatin-344 leads on the muscle & body-composition axis (5.0/5).
Which has more research, Follistatin-344 or KPV?
Follistatin-344 has 5 approved studies indexed (Human evidence); KPV has 6 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Follistatin-344 and KPV?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Follistatin-344 vs KPV?
Follistatin-344: no community-reported effects logged yet. KPV: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Follistatin-344 or KPV FDA-approved?
Follistatin-344 is a research-use compound and is not FDA-approved. KPV is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is KPV better than Follistatin-344?
For inflammation, KPV has the edge; for muscle, Follistatin-344 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Follistatin-344 and KPV are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.